Shares of Diploma PLC (LON:DPLM - Get Free Report) reached a new 52-week high on Thursday after Berenberg Bank raised their price target on the stock from GBX 5,750 to GBX 6,350. Berenberg Bank currently has a buy rating on the stock. Diploma traded as high as GBX 5,565 ($75.32) and last traded at GBX 5,540 ($74.99), with a volume of 239194 shares trading hands. The stock had previously closed at GBX 5,440 ($73.63).
Other analysts have also issued research reports about the company. Jefferies Financial Group upped their price objective on Diploma from GBX 4,500 to GBX 5,200 and gave the company a "hold" rating in a research note on Thursday. JPMorgan Chase & Co. reiterated a "neutral" rating and set a GBX 4,440 target price on shares of Diploma in a research note on Wednesday, August 6th. Finally, Shore Capital restated a "hold" rating and issued a GBX 5,100 price target on shares of Diploma in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Diploma presently has an average rating of "Hold" and a consensus target price of GBX 5,238.
Read Our Latest Stock Analysis on Diploma
Diploma Trading Up 1.8%
The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The stock has a market capitalization of £7.43 billion, a price-to-earnings ratio of 4,456.96, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. The business has a fifty day simple moving average of GBX 5,260.35 and a 200 day simple moving average of GBX 4,609.28.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.